Interleukin-2 therapy of cancer.
The aim of this review is to evaluate the results of IL-2 therapy of cancer two decades after the first experiments and to discuss whether and which results of local, systemic and adjuvant IL-2 therapy in preclinical models can be translated into clinics. The attention is also focused on the development and utilization of the IL-2 gene-modified tumour vaccines for therapeutic purposes. The prospects and limitations of both, IL-2 therapy and IL-2 gene therapy are discussed.